[Pulmonary arterial hypertension--a rare form of pulmonary hypertension].
Schenk
Maren
M
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics; D002648:Child; D002908:Chronic Disease; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D065128:Endothelin Receptor Antagonists; D019317:Evidence-Based Medicine; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005858:Germany; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D006782:Hospitals, Special; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology / Q000235:genetics; D010102:Oxygen Inhalation Therapy; D010348:Patient Care Team; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D035583:Rare Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; D014665:Vasodilator Agents; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II; D006162:Guanylate Cyclase; C542595:riociguat